-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $21

Benzinga·02/06/2026 20:37:52
Listen to the news
JP Morgan analyst Sebastian Sandler maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and raises the price target from $20 to $21.